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The 37/67kDa laminin receptor (LAMR) is a multifunctional protein, acting as an extracellular receptor, localizing to the nucleus,
andplayingrolesinrRNAprocessingandribosomeassembly.LAMRisimportantforcellviability;however,itisunclearwhichof
itsfunctionsare essential.We developed asilent mutant LAMR construct, resistant tosiRNA,to rescue the phenotypic effects of
knockingdownendogenous LAMR,whichincludeinhibition ofproteinsynthesis,cellcyclearrest, andapoptosis.Inaddition,we
generated a C-terminal-truncated silent mutant LAMR construct structurally homologous to the Archaeoglobus fulgidus S2
ribosomal protein and missing the C-terminal 75 residues of LAMR, which displays more sequence divergence. We found that
HT1080 cells stably expressing either silent mutant LAMR construct still undergo arrest in the G1 phase of the cell cycle when
treated with siRNA. However, the expression of full-length silent mutant LAMR rescues cell viability, whereas the expression of
the C-terminal-truncated LAMR does not. Interestingly, we also found that both silent mutant constructs restore protein
translation and localize to the nucleus. Our ﬁndings indicate that the ability of LAMR to regulate viability is associated with its
C-terminal 75 residues. Furthermore, this function is distinct from its role in cell proliferation, independent of its ribosomal
functions, and may be regulated by a nonnuclear localization.
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The 37/67kDa laminin receptor (LAMR), as a cell surface
receptor, has roles in cell migration,
1 invasion,
2 angiogen-
esis,
3 and extracellular matrix remodeling.
4,5 LAMR also
serves as a cellular receptor for many pathogens, including
prion protein,
6 bacteria,
7 and numerous viruses.
8–11 Since its
initial discovery, however, LAMR was determined to be a
highly conserved ribosomal protein that acquired its extra-
cellular functions during evolution.
12 The human sequence of
LAMR has homologs in many species, including prokaryotes;
Archaea encode a protein that is 40% identical to LAMR,
which places it as a member of the S2 family of ribosomal
proteins.
13 Thecrystal structure ofrecombinant human LAMR
from residues 1 to 220, generated by our laboratory, shows
structural homology with the Archaeoglobus fulgidus S2
ribosomal protein.
14 Such sequence and structural conser-
vation implies that LAMR is important for basic cellular
functioning. Indeed, yeast homologs of LAMR are essential
for cell viability,
15 having roles in 20s–18s rRNA processing
and ribosome assembly.
16 LAMR homologs are ribosome
associated in higher organisms as well, including plant
17 and
mouse,
18 although, whether or not the ribosomal functions of
LAMR are important for cell viability in higher organisms
remains unclear. Reduction of LAMR expression in HeLa cells
results in apoptosis;
19 however, translation was reportedly not
affected. Apoptosis was observed in Hep3b cells upon
reduction of LAMR, but the effect on translation was not
reported.
20 L A M Rc a na l s ol o c a l i z et ot h en u c l e u sa n di n t e r a c t
with histones;
21 therefore, nuclear functions of LAMR may have
a role in cell viability. LAMR has been implicated incell signaling
pathways that are important for cell survival as well.
22
Interestingly, sequence homology between human LAMR
and homologs in invertebrates resides only within the ﬁrst
two-thirds of the molecule, whereas the C-terminal sequence
is more divergent. The human LAMR sequence is 73.5%
homologous to that of hydra from residues 1 to 218, but only
20% homologus in the C-terminal 76 residues.
23 In contrast,
the entire human LAMR sequence is highly conserved among
vertebrates as the human LAMR sequence displays 498%
homology with the mouse, bovine, and rat sequences.
24
C-terminal divergence among higher organisms is considered
to be the process by which LAMR acquired its extracellular
functions. It may have also enabled LAMR to become a
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to serve as a precursor to the 67kDa LAMR,
25 which has
only been observed in vertebrates and is dependent on
posttranslational modiﬁcations.
26,27 Extraribosomal functions
associated with the C terminus of LAMR may also have
enabled alternative mechanisms to regulate cell viability in
higher organisms, including nuclear localization.
The elucidation of how LAMR regulates cell survival
is important from a therapeutic standpoint. LAMR is over-
expressed in many different types of cancers and is consi-
dered a prognostic factor for determining the severity of
tumors.
28 Transplanted tumor cells with reduced expression
of LAMR grow slower in vivo, resulting in prolonged survival
of recipient mice.
29 Furthermore, the green tea polyphenol
( )-epigallocatechin-3-gallate (EGCG) targets tumors using
LAMR as a cellular receptor
30 and induces G1 arrest and
apoptosis in multiple myeloma cells.
31 Previously, we have
shown that the reduction of LAMR expression in HT1080
human ﬁbrosarcoma cells results in G1-phase cell-cycle
arrest.
32 We found cell cycle- and survival-related genes to
be altered at the mRNA and protein level in a manner
consistent with these observations. We also found protein
translation to be dramatically reduced as knockdown of
LAMR in HT1080 cells leads to fewer 40s subunits and
80s monosomes, as well as an increase in unassociated
60s subunits. These results were consistent with yeast
studies and show that LAMR can serve as a critical compo-
nent of the translational machinery in mammalian cells.
In turn, HT1080 cells with reduced LAMR expression have
an impaired ability to grow tumors in vivo.
In this study, we used a silent mutant LAMR, construct
resistant to siRNA, to rescue cell viability and translation
in siRNA-treated HT1080 cells. Furthermore, using a silent
mutant 1–220 truncated LAMR construct, homologous to the
A. fulgidus S2 ribosomal protein and devoid of the C-terminal
75 residues, we clariﬁed whether cell viability in HT1080 cells
is dependent on the highly conserved ribosomal functions
of LAMR.
Results
Silent mutant LAMR constructs are resistant to siRNA
and rescue the phenotypic effect of knocking down
endogenous LAMR. We mutated the third base of 6 codons
within the coding region of LAMR targeted by siRNA (siLAMR)
to generate a silent mutant cDNA/mRNA sequence that
still encodes a wild-type protein but is resistant to siLAMR
(Figure 1). To distinguish from endogenous LAMR, silent
mutant LAMR (silMUT) was cloned with an N-terminal ﬂag tag
and introduced into the human ﬁbrosarcoma HT1080 cell line.
In addition, we introduced silent mutations and an N-terminal
Figure 1 Constructing silent mutant LAMR. The coding sequence of LAMR (accession no. NM_001012321.1) is shown along with the sequence that siLAMR targets
(bold). The third base pair of each codon (underlined) within this region was changed as displayed by sequence alignment. The last residue of silMUT
220 is bold and shaded
gray. A schematic of FLAG-tagged silMUT and silMUT
220 and the region that siLAMR targets is shown below the coding sequence. Numbers represent every 50 residues of
LAMR starting with 1 at the N terminus (N), and ending with 295 at the C terminus (C). Shaded area represents the proposed transmembrane region of LAMR
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Cell Death and Diseaseﬂag tag into a 1–220 residue LAMR construct previously used
to generate a crystal structure. This silent mutant construct
(silMUT
220), missing the C-terminal 75 residues of LAMR, is
homologous to the A. fulgidus S2 ribosomal protein. We
selected several clonally derived HT1080 cell lines that stably
express silMUT and silMUT
220. Although we performed
experiments with all selected cell lines, yielding similar results,
we report herein our ﬁndings with one of each. silMUT,
silMUT
220, and parental HT1080 (WT) cells were transfected
with either siLAMR or a ﬂuorescently labeled nontargeting
control siRNA (siGLO) and analyzed for total LAMR protein
expression. Four days after transfection, endogenous LAMR is
reduced in all cells treated with siLAMR (Figure 2a, top panel).
Exogenous silMUT LAMR, detected by both an antibody for
LAMR (Figure 2a, arrow) and an antibody for the FLAG tag
(Figure 2b, middle), is not reduced by siLAMR treatment but
rather appears to be increased in expression compared with
siGLO-treated silMUT cells. silMUT
220 is not readily detected
by the antibody we used for LAMR as it is missing a part of its
C-terminal epitope. However, using an antibody for the FLAG
tag, we observed that silMUT
220 LAMR protein expression
(Figure 2b, right), is not reduced by siLAMR. We also observed
that siLAMR-treated silMUT and silMUT
220 cells display higher
LAMR mRNA expression levels than do siLAMR-treated WT
cells (Supplementary Figure 1).
As visualized by microscopy, WT cells treated with siLAMR
are reduced in number and cell size with many rounded cells
(Figure 2b, top). In contrast, silMUT cells treated with siLAMR
have normal morphology with a phenotype similar to cells
treated with siGLO (Figure 2b, middle). It should be noted that
similar results were obtained with several additional FLAG-
tagged silMUT stable clones (data not shown) and stable cell
linesthatexpresseitheruntaggedorC-terminalv5/his-tagged
silMUT LAMR constructs (Supplementary Figure 2). Con-
versely, cell lines that stably express nonmutated exogenous
LAMR do not rescue the phenotypic effect of siLAMR (data
not shown). The phenotype of silMUT
220 cells treated with
siLAMR does not appear to be as severe as in WT cells
(Figure 2b, bottom), although siLAMR-treated silMUT
220 cells
are still smaller in size (including rounded cells) than their
siGLO-treated counterparts. This suggests that unlike full-
length silMUT, silMUT
220 LAMR is unable to fully restore the
phenotypic effect of siLAMR.
Silent mutant LAMR cells still undergo G1-phase
cell-cycle growth arrest. Analyzing the cell-cycle proﬁle
of WT, silMUT, and silMUT
220 cells, we found that all cell
lines are arrested in the G1 phase of the cell cycle 4 days
after treatment with siLAMR. Overall, 68% of WT, 72% of
silMUT, and 62% of silMUT
220 siLAMR-treated cells are in
the G1 phase of the cell cycle compared with 40, 47, and 36%
for their siGLO-treated controls, respectively (Figure 3a).
Furthermore, only 18% of WT, 16% of silMUT, and 30% of
silMUT
220 siLAMR-treated cells are in the S phase compared
Figure2 SilentmutantLAMRproteinexpressionandcellphenotype.(a)WesternblotanalysisofLAMRproteinexpressioninWT,silMUT,andsilMUT
220cells4daysafter
transfection with siLAMR and siGLO. Antibodies against LAMR (top panel) and FLAG (bottom panel) were used to detect expression of endogenous and exogenous LAMR
proteinexpressionlevels,respectively.Full-length silMUT LAMRruns slightly higher thanendogenousLAMR (37kDa) andcan be detectedwith antibodiesfor LAMR(arrow).
silMUT
220 is not detected by the antibody used for LAMR and runs at B25kDa. Blots represent three separate transfections. (b) Images of WT, silMUT, and silMUT
220 cells
treated with siLAMR and siGLO 4 days after transfection. Images are indicative of at least three separate transfections
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Cell Death and Diseasewith 49, 40, and 52% of siGLO-treated cells, respectively.
While analyzing cell-cycle proﬁles, we noticed that B9% of
siLAMR-treated WT cells are in the sub-G1 phase 4 days after
transfection, indicative of cells undergoing apoptosis
(Figure 2a). Interestingly, we found no increase in a sub-G1
population for silMUT cells treated with siLAMR; however,
silMUT
220 cells treated with siLAMR display an increase in the
sub-G1 population similar to WT cells. The percentages of
cells in G1, S, and sub-G1 for each cell line are shown in
Figure 2b (left, middle, and right panel, respectively). These
results indicate that although all siLAMR-treated cells are still
arrested in the G1 phase of the cell cycle, full-length silMUT
LAMR rescues the apoptotic effects of reducing endogenous
LAMR, whereas the C-terminal-truncated silMUT
220 LAMR
does not.
The C-terminal 75 residues of LAMR are required for
maintaining cell viability. To further analyze cell viability,
we stained siLAMR- and siGLO-treated WT, silMUT, and
silMUT
220 cells 3–6 days after transfection with MitoTracker
Deep-Red (Invitrogen, Carlsbad, CA, USA), a ﬂuorescent
dye that stains the mitochondria only in viable cells. Cell
viability was accessed by ﬂuorescence-activated cell sorting
(FACS) with forward and side scatter (Figure 4a, left), as well
Figure 3 silMUT and silMUT
220 cells still undergo G1-phase cell-cycle growth arrest. (a) Cell cycle proﬁles of WT (top), silMUT (middle), and silMUT
220 (bottom) cells
treatedwithsiLAMR(left)andsiGLO(right)4daysaftertransfection.PercentagesofcellsintheG1,S,andsub-G1phasesareindicated(arrows).Plotsarerepresentativeofat
least three separate transfections. (b) The percentages of cells in the G1 (left), S (middle), and sub-G1 phases (right) 4 days after transfection are summarized. Bar¼S.E.M.
Statistical analysis was performed using a standard Student’s t-test to generate P-values. All P-values are two-tailed. ***Po0.0005. **Po0.005
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Cell Death and Diseaseas MitoTracker (Figure 4a, right). Viewing side scatter 5 days
after transfection, we observed that WT and silMUT
220 cells
treated with siLAMR develop a large population of nonviable
cells (red rectangle), whereas silMUT cells do not. Overall,
46% of siLAMR-treated WT and 28% of silMUT
220 cells are
in this nonviable population, compared with only 8% of
siLAMR-treated silMUT cells. Similar results were obtained
with MitoTracker (Figure 3a, right). Overall, 51% of siLAMR-
treated WT and 37% of silMUT
220 cells are negative for
MitoTracker compared with only 8% of siLAMR-treated
silMUT cells. The percentage of nonviable cells for the
entire time course, determined by MitoTracker, is shown in
Figure 4b.
Furthermore, using side scatter, we gated the most
dense population of viable siGLO-treated WT, silMUT, and
silMUT
220 cells (Figure 4a left panel, right plots, 42, 40, and
52%, respectively). Each gate was applied to its respective
cell line treated with siLAMR. We found that viable WT cells
treated with siLAMR become smaller and more granular,
as determined by their shift in forward and side scatter,
respectively(12%ofcellsremaininthegateappliedforsiGLO
viable cells). silMUT
220 treated with siLAMR also become
smaller (23% of cells remain in the gate applied for siGLO
viable cells). In contrast, viable siLAMR-treated silMUT cells
have the same size and morphology as siGLO-treated silMUT
cells (36% of cells remain in the gate applied for siGLO viable
Figure 4 The C-terminal 75 residues of LAMR are required for maintaining cell viability. (a) FACS analysis of siLAMR- and siGLO-treated WT (top), silMUT (middle), and
silMUT
220 (bottom) cells 5 days after transfection. Cell viability was assessed through forward and side scatter (left panel), and the MitoTracker Deep-Red stain (right panel).
NonviablecellpopulationsweregatedinsiLAMR-treatedWTcells(redrectangle)andappliedtoallplotstodeterminethepercentageofnonviablecells,asindicated.Themost
dense viable cell population was gated in each siGLO-treated plot (red circle, left panels) and applied to siLAMR plots of each respective cell line to determine changes in cell
size/morphology. Each plot is indicative of at least three separate transfections. (b) The percentage of nonviable cells 3–6 days after transfection, according to MitoTracker
Deep Red and normalized to siGLO-treated cells, are summarized. Bar¼S.E.M. Statistical analysis was performed using a two-way ANOVA to generate P-values.
***Po0.0005
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Cell Death and Diseasecells), indicating that morphological functions are also
restored by silMUT LAMR. In all, the viability/morphology
results from our FACS analysis are consistent with the rescue
of phenotypic effects we observed by microscopy (Figure 1),
and indicate that the C-terminal residues of LAMR are
required for maintaining cell viability.
The C-terminal 75 residues of LAMR are not required for
ribosomal functions. As silMUT
220 is structurally homo-
logous to the A. fulgidus S2 ribosomal protein, we reasoned
that it should maintain all ribosomal functions of LAMR, and
therefore its inability to rescue viability must be due to an
extraribosomal function. To clarify whether the ribosomal
functions of LAMR are required for cell viability, we measured
protein synthesis in WT, silMUT, and silMUT
220 cells treated
with siLAMR and siGLO 3–6 days after transfection. Five
days after transfection, translation in siLAMR-treated WT
cells is dramatically reduced, whereas that in siLAMR-treated
silMUT and silMUT
220 cells appears normal (Figure 5a). It
should be noted that translation appears to be higher in
control siGLO-treated WT cells than in siGLO-treated silMUT
and silMUT
220 cells, which may be due the clonal selection of
both cell lines. Therefore, protein synthesis for the entire time
course was quantiﬁed by scintillation counting (Figure 5b).
The percentage of translation for WT, silMUT, and silMUT
220
siLAMR-treated cells, compared with that of their respective
siGLO-treated cells, is shown. Surprisingly, the trend of
translation inhibition is similar for all cell lines 3 and 4 days
after transfection, although siLAMR-treated silMUT and
silMUT
220 do have higher protein synthesis levels than do
WT siLAMR cells 4 days after transfection (31 and 37%
compared with 14%, respectively). Five days after trans-
fection, siLAMR-treated WT cells have a modest increase
in protein synthesis to 25% of siGLO-treated WT cells.
However, siLAMR-treated silMUT and silMUT
220 cells
dramatically increase their protein synthesis up to 60% and
74, respectively. These results indicate that both silMUT
and silMUT
220 LAMR restore protein translation in siLAMR-
treated cells, thus showing that the C-terminal 75 residues
of LAMR are not required for ribosomal functions.
The C-terminal 75 residues of LAMR are not required for
nuclear localization. As LAMR was previously shown to
interact with histones and localize to the nucleus, we decided
to see whether endogenous, silMUT, and silMUT
220 LAMR
can be detected in HT1080 nuclear extracts by western blot.
The nuclear marker Lamin A/C and the cytosolic marker HSP
90-a/b show that we successfully separated both fractions
(Figure 5, top and second panel, respectively). We found
endogenous LAMR to be both cytosolic and nuclear in all cell
lines (Figure 5, third panel, LAMR). Furthermore, we found
that both silMUT and silMUT
220 are cytosolic and nuclear as
well. Therefore, our results show that LAMR localizes to the
nucleus in HT1080 cells and that the C-terminal 75 residues
are not required for this process.
Discussion
Reduction of LAMR expression by siRNA results in trans-
lation inhibition, G1-phase cell-cycle arrest, and apoptosis.
Therefore, we had to use a transient siRNA system to study
LAMR. This complicates determining the kinetics of our
observations, as well as identifying which functions/localiza-
tions of LAMR (namely ribosomal, nuclear, extracellular) are
important for proliferation and cell viability. Our silent mutant
LAMR system addresses these issues by providing a novel
way in which to study the multiple functions of LAMR in
Figure 5 The C-terminal 75 residues of LAMR are not required for ribosomal
functions.(a)Inall,20mgofproteinfrom
35S-methionine-labeledlysateswasloaded
for SDS-PAGE to detect newly synthesized proteins (top panel). Lysates were also
used for western blot analysis to detect endogenous LAMR (second panel),
exogenous silMUT and silMUT
220 LAMR (third panel), and b-actin (fourth panel).
Blots represent protein synthesis 5 days after transfection and are indicative of at
least three separate transfections. (b) Newly synthesized protein was quantiﬁed by
scintillation counting 3–6 days after transfection. Equal volumes of siLAMR and
siGLO lysates were used for counting and normalized according to protein
concentration.
35S-methionine scintillation counts for siLAMR-treated cells are
summarized as a percentage of siGLO-treated cells for each respective cell line.
Each percentage is representative of at least three separate transfections.
Bar¼S.E.M. Statistical analysis was performed using a two-way ANOVA to
generate P-values. ***Po0.0005
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Cell Death and Diseasea cellular environment. Interestingly, silMUT LAMR rescues
different functions of LAMR separately. We observe that
siLAMR-treated silMUT cells still undergo cell cycle arrest
(Figure 3) and that restoration of protein synthesis is delayed
(Figure 5). This contrasts with the rescue of morphology
and cell viability, which happens during times of cell-cycle
arrest and translational inhibition (Figure 4). The inability of
exogenous LAMR to rescue all phenotypes resulting from
inhibitionofendogenousLAMRhaspreviouslybeenobserved
in another system as well.
33 It is possible that there are
thresholdlevelsofLAMRexpressionrequiredforeachcellular
function it regulates and thus with limited expression of
exogenous LAMR, only certain functions can be restored. In
this case, functions required for cell viability would be restored
before those for translation and proliferation as they are more
essential. This is suggested by studies in yeast, which have
two copies of the lamr gene. Disruption of one gene leads to
inhibition of cell growth, whereas knockout of both gene
copies is lethal.
15
LAMRcDNAclonedfromyeasthasbeenpreviouslyusedto
complement double mutant yeast strains lacking LAMR to
restore cell viability.
16,34 In addition, exogenous LAMR has
been expressed to rescue both lethal and viable phenotypes
in Drosophila due to mutations of the endogenous gene.
33 We
are the ﬁrst to achieve such rescue in mammalian cells.
Although studies conducted in yeast and Drosophila con-
cludedthattherescueofcellviabilityismostlikelyattributedto
the ribosomal functions of LAMR, our results with silMUT
220
cells indicate that extraribosomal functions of LAMR are
importantforthisprocess.WefoundthatsilMUT
220LAMRcan
restore protein synthesis in a delayed manner similar to full-
length silMUT LAMR (Figure 5). This is consistent with
sequence analysis showing that, as a ribosomal protein, the
ﬁrst two-thirds of LAMR are highly conserved, whereas the C
terminus is more divergent among higher organisms (most
likely to acquire extracellular functions). This also supports
our structural analysis showing the homology between the
1–220 LAMR and the A. fulgidus S2 ribosomal protein.
14
However, despite retaining ribosomal functions, silMUT
220 is
unable to rescue cell viability (Figure 4), indicating that
extraribosomal functions of the C-terminal 75 residues are
essential for this process.
Furthermore, we have shown that the C-terminal 75
residues of LAMR are not required for nuclear localization
(Figure 6), as silMUT
220 localizes to the nucleus in a similar
capacity as full-length silMUT and endogenous LAMR. Future
studies are required to determine whether silMUT
220 is
functional in a nuclear context. Although silMUT
220 may
localize to the nucleus, its inability to rescue cell viability may
be due to a lack of the necessary residues/domains required
for nuclear interactions. Still, these ﬁndings suggest that the
functionsofLAMR associatedwith viability may bedependent
on a nonnuclear localization.
As mentioned earlier, LAMR was initially discovered as a
cell surface receptor for laminin. Surface localization of LAMR
may therefore be important for maintaining cell viability.
Othershaveshownthatthe37kDaLAMR isexpressedonthe
cellsurfaceofnumerouscelltypes,
6includingHT1080cells.
35
However, we were unable to detect 37kDa LAMR at the cell
surface of our HT1080 cells (data not shown). Surface
localization may instead be reserved for a different form of
LAMR, in particular the 67kDa dimer. As this molecule is only
observed in vertebrates, it is believed that C-terminal
sequence divergence has a role in its formation. Therefore,
silMUT
220 may be missing the required residues/domain to
form a dimer. Alternatively, silMUT
220 may still be able to form
a dimer, but one that is missing residues important for
essential contacts with the extracellular matrix. It should
be noted that three binding sites for laminin have been dis-
covered on LAMR thus far: residues 161–181 (peptide G),
36
205–229,
37 and the C-terminal 53 residues.
38 Although
silMUT
220 contains the peptide G binding region and is
functional in laminin-1 binding,
14 it is missing portions or all
of the other two laminin-binding sites. The laminin-binding
regions missing in silMUT
220 may be required for interactions
important for cell viability. Interestingly, cleavage of LAMR by
stromelysin-3, which separates the laminin-binding regions of
LAMR from the cell surface, may have a role in promoting
apoptosis.
39 Therefore, the expression of silMUT
220, missing
these binding sites, may have a similar effect.
In conclusion, our silent mutant rescue system has deter-
mined that translation and cell viability are regulated in distinct
manners by LAMR and that the extraribosomal functions of
LAMR are required for maintaining cell viability. In addition,
we used truncated LAMR to examine and distinguish its role
in proliferation, translation, morphology, and viability. Further
use of silMUT
220 as well as additional truncated/mutated
silent mutant LAMR constructs, will ultimately help deﬁne the
multiple functions/localizations of LAMR.
Materials and Methods
Cloning. The LAMR coding sequence was cloned into the pcDNA 3.1/c
N-terminal ﬂag vector (Invitrogen) using BamH1 and Xho1 restriction sites. Primers
used were as follows:
Figure 6 The C-terminal 75 residues of LAMR are not required for nuclear
localization. In all, 20mg of protein was loaded for western blot from both cytosolic
and nuclear fractions. Blots were probed with Lamin A/C (panel 1) and HSP 90-a/b
(panel2)fornuclearandcytosolicmarkers,respectively.Fractionswerealsoprobed
for endogenous LAMR (panel 3) and exogenous FLAG-tagged silMUT and
silMUT
220 LAMR (panel 4)
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Cell Death and DiseaseForward primer: 50-GGATCCTCCGGAGCCCTTGATGT-30 and reverse primer:
50-CTCGAGTTAAGACCGGTCAGTGGTTGCTCC-30.
This vector served as a backbone for generating six silent mutations in the LAMR
coding sequence using the Quick change II XL site-directed Mutagenesis kit
(Stratagene, La Jolla, CA, USA). Primers used for silent mutant cloning were as follows:
Forward primer: 50-GGGAAGTTCTACGTATGCGAGGTACTATCTCCCGTGAA
CACCC-30 and reverse primer: 50-GGGTGTTCACGGGAGATAGTACCTCGCAT
ACGTAGAACTTCCC-30.
To generate the C-terminal-truncated silent mutant LAMR construct, the above
forward primer was used with a reverse primer starting at the codon for the 220th
residue of LAMR (out of 295).
Reverse truncated primer: 50-CTCGAGTTACTTCTCAGCAGCAGCCTGCCC-30.
Gene analysis. Extraction of total cellular RNA was performed using the RNA
easy mini kit (Qiagen, Valencia, CA, USA). In all, 0.5mg of RNA was used for the
iScript cDNA synthesis kit (Bio-Rad, Hercules, CA, USA). Overall, 0.5ml of cDNA
was usedtodetermineLAMRexpression levelsby quantitativereal-time PCRusing
a Bio-Rad iCycler. Human GAPDH was chosen as the housekeeping gene for
comparative analysis between samples. Human LAMR and GAPDH primers were
designed and used as described previously.
40 The fold change in laminin receptor
relative to the GAPDH endogenous control was determined by fold change¼
2 (CT),whereCT¼CT(lamininreceptor) CT(GAPDH)and(CT)¼CT(silMUT) 
CT(WT). CT is the threshold cycle determined by ﬂuorescence data collection.
Cellculture. TheHT1080celllinewasobtainedfromtheATCC(Manassas,VA,
USA). Silent mutant LAMR cell lines were generated by transfecting HT1080 cells
with pCDNA 3.1/c N-terminal ﬂag vectors containing either full-length or 1–220
C-terminal-truncated silent mutant LAMR. Lipofectamine 2000 (Invitrogen) was
used for transfection and clonal stable cell lines were selected with neomycin.
Endogenous LAMR expression was inhibited using the predesigned siGENOME
individual oligonucleotide no. 3 targeting LAMR (Dharmacon, Lafayette, CO, USA).
Control nontargeting siGLO RISC-free siRNA and DharmaFECT 4 transfection
reagent were also purchased from Dharmacon. A ﬁnal concentration of 100nM of
siRNA was used for each transfection. To analyze phenotypic effects of siRNA,
cellswereimagedusingaNikonEclipseTE200-Emicroscope(Tokyo,Japan)using
the NIS-Elements BR-2.30 program (Nikon).
Cell proliferation/viability. For cell-cycle proﬁle analysis, cells were
permeabilized overnight in 100% ethanol at 41C then stained with ﬁnal
concentrations of 50mg/ml of propidium Iodide (Invitrogen) and 100mg/ml of
RNAse A (Sigma-Aldrich, St. Louis, MO, USA). Cells were analyzed using a BD
FACScan machine (BD Biosciences, San Jose, CA, USA) and the percentages of
cells in sub-G1,G 1, and S phase were determined using the Modﬁt LT 3.2 program
(Verity software house, Topsham, ME, USA).
Cell morphology/viability was further analyzed by forward/side scatter FACS
analysis and using the Deep-Red MitoTracker stain (Invitrogen). Analysis was
performed using a BD LSRII machine. Viable/nonviable cells were gated and
quantiﬁed using the Flowjo 8.2 program (Tree Star, Ashland, OR, USA).
Protein analysis. For western blots, cells were harvested in Mammalian
Protein Extraction Reagent (MPER) (Pierce, Rockford, IL, USA). A total of 20mgo f
total protein was used for SDS-PAGE and transferred to PVDF membrane. LAMR
protein expression was detected using the rabbit polyclonal antibody H-141,
purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). This antibody
recognizes epitopes in the C terminus of LAMR and predominantly detects the
37kDa form. Flag-tagged silent mutant LAMR was detected using the Flag M-2
antibody from Stratagene.
To study translation, cells were metabolically labeled with
35S-methionine
(20mCi/ml) (Perkin-Elmer, Waltham, MA, USA) in DMEM lacking methionine (MP
Biomedicals, Santa Ana, CA, USA) supplemented with 0.1% FCS for 2h at 371C
(pulse). Normal growth medium was then added and cells were incubated for
an additional 90min at 371C (chase). Cells were harvested in MPER and
20mg of protein was loaded onto SDS-PAGE for analysis. To quantify protein
synthesis, 4ml of protein lysate (12–16mg total protein) was precipitated with
10% TCA for 20min at 41C. Precipitated protein was vacuum ﬁltered through
Whatman glass microﬁber ﬁlters (Whatman, Piscataway, NJ, USA) and washed
once with 5% TCA then 95% ethanol. Filters were dried under a heating lamp then
immersed in 3ml of scintillation ﬂuid and counted using a Beckman LS 3801
scintillation counter (Beckman, Brea, CA, USA).
Nuclear extraction. Nuclear extracts were collected from 2 10
6 WT,
silMUT, and silMUT
220 cells using the Affymetrix Nuclear Extraction Kit (Affymetrix,
Fremont,CA,USA).Theprocedurewas carriedoutaccordingtothemanufacturer’s
protocol. The number of cells used for extraction, as well as buffer volume, were
scaled up twofold.
Statistical analysis. Statistical analysis for cell-cycle data was performed
using a standard Student’s t-test. The P-values generated are two-tailed. Statistical
analysis for MitoTracker staining (viability), scintillation counting (translation),
and mRNA expression was performed with two-way ANOVA. All statistics were
generated using GraphPad Prism, version 3.0cx for Macintosh (GraphPad
Software, San Diego, CA, USA).
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